Form 8-K - Current report:
SEC Accession No. 0001837607-25-000032
Filing Date
2025-04-25
Accepted
2025-04-25 16:06:13
Documents
14
Period of Report
2025-04-22
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K aeon-20250422x8k.htm   iXBRL 8-K 35694
  Complete submission text file 0001837607-25-000032.txt   167113

Data Files

Seq Description Document Type Size
2 EX-101.SCH aeon-20250422.xsd EX-101.SCH 4044
3 EX-101.DEF aeon-20250422_def.xml EX-101.DEF 2869
4 EX-101.LAB aeon-20250422_lab.xml EX-101.LAB 17853
5 EX-101.PRE aeon-20250422_pre.xml EX-101.PRE 10675
16 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20250422x8k_htm.xml XML 5053
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40021 | Film No.: 25873931
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)